![]() |
|
|
Vol. 299, Issue 1, 377-384, October 2001
-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/Kainate
Receptors: Secure Blockade of Ischemic Neuronal Death
Departments of Neuroscience and Pharmacology and Center for the
Interventional Therapy of Stroke and Alzheimer's Disease, Ajou
University School of Medicine, Suwon, Korea (S.Y.S., B.J.G.);
Antibiotics Research Laboratory, Korea Research Institute of Bioscience
and Biotechnology, Taejon, Korea (B.-S.Y., I.J.R., S.O., I.D.Y.);
Department of Ophthalmology, Catholic University Medical College,
Seoul, Korea (J.-S.C., C.-K.J.); and Department of Biology and Center
for Cell Signaling Research, Ewha Womans University, Seoul, Korea
(S.-Y.C., J.-M.C.)
Complestatin, a peptide derived from Streptomyces, was
found to protect cultured cortical neurons from excitotoxicity induced by N-methyl-D-aspartate (NMDA),
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), or
kainate. This neuroprotective behavior of complestatin was
attributed to a blockade of Ca2+ ion entry and
accumulation, after the activation of NMDA and AMPA/kainate receptors.
Complestatin reversibly interfered with NMDA- and AMPA-mediated
excitatory synaptic transmission. Complestatin also protected cortical
neurons from prolonged deprivation of oxygen and glucose, more
effectively than combined antagonists of NMDA and AMPA/kainate
receptors. Neurotoxicity, evolving within 1 to 2 days after continuous
exposure to combined NMDA and AMPA/kainate antagonists, was not
observed in cortical cell cultures that were exposed to complestatin.
Finally, complestatin dose dependently prevented neuronal death
evolving within the inner nuclear and ganglion cell layers, after
transient retinal ischemia. We conclude that complestatin possesses
novel pharmacological properties that effectively prevent
excitotoxicity under certain pathological conditions.